Noophen, capsules 250 mg 20 pcs

Noophen is a nootropic drug, a derivative of gamma-aminobutyric acid and phenylethylamine. It has tranquilizing properties, stimulates memory and learning ability, increases physical ability to work, eliminates psycho-emotional tension, anxiety, fear and improves sleep. It does not affect the choline and adrenoreceptors.

The drug prolongs the latent period and shortens the duration and severity of nystagmus. Significantly reduces manifestations of asthenia and vasovaginal symptoms, including headache, feeling of heaviness in the head, sleep disturbance, irritability, emotional lability, increases mental performance, improves well-being, increases interest and initiative, motivation to active work without sedation or agitation.

In contrast to tranquilizers, Noophen improves psychological parameters (attention, memory, speed and accuracy of sensory-motor reactions). Formation of addiction and dependence on the drug and withdrawal syndrome are not observed.

Pharmacokinetics

Absorption and distribution

After oral administration the drug is well absorbed and penetrates into all tissues of the body. About 0.1% of γ-amino-β-phenyl butyric acid hydrochloride of the administered dose of the drug penetrates into brain tissue; in patients of young and elderly age the penetration through the HEB may increase. After 3 h γ-amino-β-phenyl butyric acid hydrochloride is detected in urine, at the same time the concentration in the brain tissue is not decreased, it is detected in the brain after another 6 h.

The drug does not accumulate in the body when repeated use.

The highest binding of γ-amino-β-phenyl butyric acid hydrochloride occurs in the liver (80%), it is not specific.

Metabolism and excretion

80-95% of the drug is metabolized in the liver to pharmacologically inactive metabolites. 5% is excreted unchanged by the kidneys. The day after administration, γ-amino-β-phenyl butyric acid hydrochloride can only be detected in the urine; it is detected in the urine 2 days after administration, but the detectable amount is 5% of the administered dose.

Indications

Active ingredient

Composition

Active ingredient:

aminophenyl butyric acid hydrochloride250 mg

Ancillary substances:

lactose monohydrate – 180 mg,

potato starch – 67.5 mg,

calcium stearate – 2.5 mg.

Composition of capsules #0 white:

Titanium dioxide (E171) – 2%, gelatin – up to 100%.

How to take, the dosage

Ingestion after a meal with water. The capsule should not be chewed.

Asthenic and anxious-neurotic states: adults – 250-500 mg 3 times a day. Maximum single dose for adults is 750 mg, for patients older than 60 years – 500 mg. If necessary, the daily dose is increased to 2.5 g. The course of treatment is 4-6 weeks.

Stuttering, tics and enuresis in children aged 8 to 14 years – 250 mg 2-3 times a day; in children over 14 years – doses for adults.

Insomnia and nocturnal anxiety in elderly patients – 250-500 mg 3 times a day.

For dizziness relief in vestibular dysfunction of infectious genesis (otogenic labyrinthitis) and Meniere’s disease: during exacerbation, 750 mg 3 times daily for 5-7 days, when expressed vestibular disorders are reduced – 250-500 mg 3 times daily for 5-7 days, then – 250 mg once daily for 5 days. In a relatively mild course of the disease – 250 mg 2 times a day for 5-7 days, then 250 mg once a day for 7-10 days.

For dizziness in dysfunction of the vestibular analyzer of vascular and traumatic genesis, 250 mg 3 times a day for 12 days.

For prevention of motion sickness in motion sickness: 250-500 mg once 1 hour before the expected trip or when the first symptoms of motion sickness appear. The anti-sickness effect of Noophen increases with increasing the dose of the drug. In case of pronounced manifestations of sea sickness (including “uncontrollable” vomiting) oral administration of the drug is of little effect even in dose of 750-1000 mg.

In combination therapy in alcohol withdrawal syndrome in order to relieve psychopathological and somatovegetative disorders during the first days of treatment the daily dose is prescribed in dose 250-500 mg 3 times a day and 750 mg at bedtime with gradual lowering of daily dose down to usual dose for adults.

Do not take a double dose to replace a missed dose.

In patients with renal and/or hepatic impairment, renal and/or hepatic function parameters should be monitored during long-term use.

In patients with impaired liver function, high doses of the drug may cause hepatotoxicity. In such patients the drug is prescribed in lower doses.

Interaction

In order to potentiate each other, Noophen® may be combined with other nootropic drugs, reducing the doses of Noophen® and the combined medications.

Longens and enhances the effects of sleeping pills, neuroleptic and anti-Parkinsonian drugs.

Special Instructions

In long-term use, the cellular blood count and liver function parameters should be monitored.

Impact on driving and operating machinery

At the time of treatment, patients should be careful when driving vehicles and engaging in other potentially dangerous activities requiring increased concentration and rapid psychomotor reactions, since CNS disorders such as drowsiness and dizziness may be observed in some patients.

Contraindications

Side effects

Nervous system disorders: drowsiness and increase of symptoms (at the beginning of treatment), dizziness, headache.

Digestive system disorders: nausea (at the beginning of treatment).

Skin and subcutaneous tissues: rarely – allergic reactions (skin rash, itching).

Hepatic and biliary tract disorders: in long-term use in high doses – hepatotoxicity.

If any of the above side effects worsen, or if the patient notices any other side effects, you should tell your doctor.

Overdose

Noophen® is mildly toxic. No cases of overdose have been reported.

Symptoms: drowsiness, nausea, vomiting, dizziness. Eosinophilia, arterial hypotension, renal disorders, fatty liver dystrophy may develop with prolonged use of high doses (intake more than 7 g).

Treatment: gastric lavage, symptomatic treatment, maintenance of vital functions. There is no specific antidote.

Pregnancy use

The use in pregnancy and during breastfeeding is not recommended because there are not enough clinical observations.

In experimental studies on animals no mutagenic, teratogenic and embryotoxic effects of the drug were found.

Similarities